Don't Buy Apellis Pharmaceuticals Before Checking Its Fundamentals!

By Naomi Wentworth • Thursday, December 14 18:26 • Permanent Link

One of the losers of today's trading session was Apellis Pharmaceuticals. Shares of the Pharmaceutical company plunged -17.0%, and some investors may be wondering if its price of $52.18 would make a good entry point. Here's what you should know if you are considering this investment:

Apellis Pharmaceuticals has moved 20.0% over the last year, and the S&P 500 logged a change of 20.8%
APLS has an average analyst rating of buy and is -29.25% away from its mean target price of $73.75 per share
Its trailing earnings per share (EPS) is $-5.23
Apellis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -10.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.63 and its forward P/E ratio is -32.0
The company has a Price to Book (P/B) ratio of 26.6 in contrast to the S&P 500's average ratio of 2.95
Apellis Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-425164128, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.